Health care services provider Encompass Health (NYSE: EHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.

Is now the time to buy EHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Encompass Health’s second quarter reflected robust demand for inpatient rehabilitation, with the company delivering revenue growth above Wall Street expectations and a double-digit gain in non-GAAP earnings per share. Management attributed the strong results to ongoing investments in clinical workforce development and capacity additions, as well as continued momentum in treating higher-acuity patient categories like stroke and brain injury. CEO Mark Tarr highlighted that the company’s patient outcomes “continue to exceed industry averages,” and cited the expansion of professional growth programs for clinical staff as a key factor behind lower turnover and reduced premium labor costs.

Looking ahead, Encompass Health’s updated outlook is underpinned by expectations for further growth in high-acuity patient volumes, continued expansion through new hospitals and bed additions, and disciplined workforce investments. CFO Douglas Coltharp noted that higher participation in career ladder programs is anticipated to drive both quality of care and operational efficiency, while also reducing reliance on contract labor. Management remains optimistic about the opportunity created by regulatory changes in North Carolina and sees the company’s ongoing technology partnerships, including AI-driven administrative tools, as potential contributors to future productivity.

Key Insights from Management’s Remarks

Management identified several business drivers that shaped both the quarter’s performance and the updated full-year guidance, from expansion in high-complexity patient care to new development projects and labor initiatives.

• Growth in high-acuity care: The company saw sustained increases in admissions for medically complex conditions, with stroke and brain injury admissions rising at a faster pace than lower-acuity categories. Management stated this mix shift contributed to improved pricing and strengthened Encompass Health’s competitive position, as treating these patients creates a “competitive moat.”
• Capacity expansion initiatives: Encompass Health opened two new hospitals and added beds to high-occupancy locations, aiming to meet strong patient demand. Management noted that additional bed and hospital openings are planned for the rest of the year, and that the pipeline of future projects remains active, particularly following regulatory changes in key states.
• Labor investment and retention: The company’s professional development and career ladder programs for nurses and therapists have led to notable improvements in staff retention and reduced turnover. According to management, turnover rates among nurses participating in these programs are significantly lower than non-participants, which has supported lower premium labor spend and enabled more rapid hospital ramp-ups.
• Pilot programs for payer denials: Management discussed ongoing challenges with Medicare Advantage plan denials for inpatient rehabilitation services. The company’s pilot “admit and appeal” program has achieved an 89% success rate in appeals, and leadership indicated plans to scale the program for certain diagnoses across more facilities.
• AI and technology adoption: The company is implementing AI-powered administrative and clinical tools, with management citing improvements in workflow automation, risk modeling, and real-time clinical auditing. While the full benefits are still ahead, these initiatives are expected to increase productivity and data-driven decision-making over time.

Drivers of Future Performance

Encompass Health’s guidance is shaped by expectations for continued volume growth in high-acuity categories, new facility openings, and workforce productivity improvements, though ongoing reimbursement and labor cost trends present key variables.

• Facility expansion pipeline: Management anticipates a meaningful contribution from new hospital openings and bed expansions, especially as regulatory changes in North Carolina open up new markets. The company is prioritizing both traditional and small-format hospitals, aiming to capture underserved demand and support long-term growth.
• Labor productivity and cost control: Higher participation in career ladder programs for nurses and therapists is expected to continue lowering staff turnover and premium labor expenses. Management stated that while wage inflation is likely to moderate, maintaining a skilled workforce is critical for handling complex cases and scaling operations efficiently.
• Regulatory and payer headwinds: The company is monitoring developments in Medicare Advantage reimbursement policies and state-level regulatory changes affecting Certificate of Need laws. While recent CMS rules are expected to deliver a modest net revenue per discharge increase, management acknowledged that payer denials and policy shifts present ongoing uncertainty for future results.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace and success of new hospital and bed expansions, particularly in newly deregulated states like North Carolina; (2) ongoing execution of workforce development and retention programs, including their impact on premium labor costs; and (3) the company’s ability to scale pilot initiatives addressing payer denials and leverage AI-driven operational improvements. Trends in high-acuity patient admissions and regulatory developments will also remain key signposts.

Encompass Health currently trades at $124.63, up from $110.90 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.